A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
23/04/2021at 10:11

EU Commission denies report on Astrazeneca lawsuit

Swedish-British pharmaceutical company Astrazeneca has not provided the agreed-upon vaccine doses, but the EU has not yet decided on legal recourse.
Photo: Dado Ruvic/REUTERS / X02714
BY RITZAU, TRANSLATED BY NIELSINE NIELSEN

In the last 24 hours, many media outlets have reported that the EU plans to file a lawsuit against the Swedish-British pharmaceutical company Astrazeneca for failing to provide the number of Covid-19 vaccine doses that are stated in its contract with the EU.

On Thursday, Ireland's Minister for Health Stephen Donnelly said that a legal case 'had been initiated', according to news media Reuters.

However, the EU Commission denies this statement, saying: "No decision to launch legal actions has been taken at this point in time".

In the Irish Parliament, Donnelly stated Ireland had joined the legal case alongside other EU countries.

The possible legal recourse revolves around the fact that Astrazeneca has failed to provide the doses that were agreed on in the contract for April, May and June, according to the minister.

The lawsuit would be played out in the Belgian court, since the parties agreed in the contract that any disputes will be handled there.

International media Politico reports that the question of possible legal recourse for Astrazeneca was raised by some EU countries' ambassadors to Brussels on Wednesday, when a majority of them supported the decision to file a suit, according to sources.

One diplomat said that the aim of the suit is to force Astrazeneca to deliver the vaccines that it promised the EU in the contract it signed. Astrazeneca has had huge supply chain problems and has been forced to warn of delays on several occasions.

The EU had intended that this vaccine would be the backbone of the first EU vaccine rollout, but in Q1, the vaccine producer could not deliver anywhere near the agreed-on amount of doses.

A failure to meet predicted supply has turned into something of a pattern for the company; the original contract stated that Astrazeneca would supply 180 million doses each quarter – but this has now been downgraded to around one third of that amount.

One high-ranking source was quoted on Wednesday as saying that the EU will not be utilizing the option of buying more doses of Astrazeneca's vaccine.

The vaccine, which is marketed under the name of Vaxzevria, has encountered problems with significant side effects and has been linked to a small number of cases of blood clots and low platelet counts among those who have received it. In several cases, this has led to death.

The vaccine has been removed from the vaccination plan in Denmark and Norway, and a number of other countries have introduced limitations on who may receive the vaccine – in many places, it is only being given to the elderly.

In Sweden, national epidemiologist Anders Tegnell has had his first dose of the Astrazeneca vaccine.

"I want to send an important signal that Astrazeneca is a fantastic vaccine for those aged 65 or over," he says to Swedish paper Corren. 

 

EU prepares to file lawsuit against Astrazeneca 

Related articles:

  • Empty vials of vaccines by Pfizer-BioNTech and AstraZeneca against Covid-19 caused by the novel coronavirus are pictured at the vaccination center in Rosenheim, southern Germany, on April 20, 2021, amid the novel coronavirus / COVID-19 pandemic | Photo: CHRISTOF STACHE/AFP / AFP

    EU prepares to file lawsuit against Astrazeneca

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Photo: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Experienced Patent Counsel

  • Principal Laboratory Technologist

  • Clinical Operational Associate

  • Head of International Sales

  • Commercial Director

See all jobs

Jobs

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Experienced Patent Counsel

  • Principal Laboratory Technologist

  • Clinical Operational Associate

  • Head of International Sales

  • Commercial Director

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge